Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Biologics and Crucell N.V. have achieved a record yield of more than 27 grams per liter in the production of IgG antibodies using PER.C6 technology. In March 2008 a yield of 15 grams per liter was reported. Higher yields can mean lower production costs and reduced risk in drug development. Also, the glycosylation of monoclonal antibodies and proteins, produced using PER.C6 technology, is fully human.

Scientists at Percivia PER.C6 Development Center , a joint venture between DSM and Crucell, have shown that they can reproduce the manufacture a record amount of product with more than 95% viability and unchanged product quality. This was achieved using standard bioreactor equipment and readily available cell culture medium. The result of this effort provides the biotechnology industry with a reliable production platform to economically manufacture large amounts of therapeutic proteins more easily.

Marcel Lubben, vice president business development at DSM Biologics, said, “We are extremely pleased with this achievement. This milestone coincides with our commitment to provide the most inherently robust manufacturing platform and ensure the utmost product quality for protein manufacturing. Our mission of only the best quality for manufacturing is echoed by the PER.C6 technology platform.”

 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics